SynthesisClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
Effectiveness and Safety of Su He Xiang Pill in the Treatment of Acute Stroke: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Synthesis in Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and ObjectiveSu He Xiang Pill (SHXP) is a traditional Chinese medicine widely used for treating acute stroke. This study systematically evaluates the efficacy and safety of SHXP to provide evidence for integrated Traditional Chinese and Western Medicine treatment approaches for acute stroke.MethodsRandomized controlled trials (RCTs) on SHXP for acute stroke were retrieved from CNKI, Wanfang, VIP, PubMed, the Cochrane Library, and other databases up to December 2024. Two reviewers independently screened literature, selected eligible studies, extracted data, and performed meta-analysis using RevMan 5.4. The primary outcome was the National Institutes of Health Stroke Scale (NIHSS); secondary outcomes included China Stroke Scale (CSS), Barthel Index (BI), Modified Rankin Scale (mRS), and adverse drug reactions (ADR).ResultsA total of 26 RCTs involving 2537 patients were included. Compared with conventional treatment alone: ① SHXP significantly reduced NIHSS scores (19 studies, MD = -2.37, 95% CI: -3.05 to -1.70, p < 0.00001) ; ② SHXP significantly improved BI scores (5 studies, MD = 9.79, 95% CI: 8.71 to 10.86, p < 0.00001); ③ No significant increase in ADR was observed (17 studies, OR = 0.56, 95% CI: 0.39 to 0.82, p = 0.002).ConclusionsSHXP exhibits significant efficacy and safety in treating acute stroke (onset within 2 weeks), supporting its use in integrated Traditional Chinese and Western Medicine to improve clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.